NZ565078A - Deuterated proton pump inhibitors such as omeprazole - Google Patents

Deuterated proton pump inhibitors such as omeprazole

Info

Publication number
NZ565078A
NZ565078A NZ565078A NZ56507806A NZ565078A NZ 565078 A NZ565078 A NZ 565078A NZ 565078 A NZ565078 A NZ 565078A NZ 56507806 A NZ56507806 A NZ 56507806A NZ 565078 A NZ565078 A NZ 565078A
Authority
NZ
New Zealand
Prior art keywords
methoxy
hydrogen
benzimidazole
trideuteriomethoxy
methyl
Prior art date
Application number
NZ565078A
Other languages
English (en)
Inventor
Bernhard Kohl
Bernd Muller
Dieter Haag
Wolfgang-Alexander Simon
Karl Zech
Michael David
Ritcher Oliver Von
Felix Huth
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of NZ565078A publication Critical patent/NZ565078A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ565078A 2005-07-26 2006-07-26 Deuterated proton pump inhibitors such as omeprazole NZ565078A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05106868 2005-07-26
PCT/EP2006/064666 WO2007012650A1 (en) 2005-07-26 2006-07-26 Isotopically substituted proton pump inhibitors

Publications (1)

Publication Number Publication Date
NZ565078A true NZ565078A (en) 2010-03-26

Family

ID=35734406

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ565078A NZ565078A (en) 2005-07-26 2006-07-26 Deuterated proton pump inhibitors such as omeprazole

Country Status (17)

Country Link
EP (1) EP1910293A1 (es)
JP (1) JP5448448B2 (es)
KR (1) KR101358509B1 (es)
CN (2) CN102134232B (es)
AR (1) AR054584A1 (es)
AU (1) AU2006274036B2 (es)
BR (1) BRPI0614039A2 (es)
CA (1) CA2615670C (es)
EA (1) EA016814B1 (es)
HK (2) HK1125098A1 (es)
IL (1) IL188773A (es)
MX (1) MX2008000901A (es)
NO (1) NO20080839L (es)
NZ (1) NZ565078A (es)
TW (1) TWI394750B (es)
WO (1) WO2007012650A1 (es)
ZA (1) ZA200800303B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615678C (en) * 2005-07-26 2015-01-20 Nycomed Gmbh Isotopically substituted pantoprazole
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
WO2008127640A2 (en) * 2007-04-11 2008-10-23 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
WO2008130863A2 (en) * 2007-04-11 2008-10-30 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
JP5714031B2 (ja) 2010-02-12 2015-05-07 エステヴェ キミカ, エス.エー. エソメプラゾールナトリウムのナトリウム塩の調製方法
CN104530003A (zh) * 2014-06-10 2015-04-22 广东东阳光药业有限公司 吡啶甲基亚磺酰基-1h-苯并咪唑类化合物的盐的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPH0643426B2 (ja) * 1986-07-25 1994-06-08 東京田辺製薬株式会社 イミダゾ〔4,5−b〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤
AU707748B2 (en) * 1994-03-25 1999-07-22 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6884429B2 (en) * 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
NO309305B1 (no) * 1999-02-19 2001-01-15 Norsk Hydro As Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater
DE10123129A1 (de) * 2001-05-02 2002-11-14 Berolina Drug Dev Ab Svedala Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel
DE10162121A1 (de) * 2001-12-12 2003-06-18 Berolina Drug Dev Ab Svedala Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel
CA2615678C (en) * 2005-07-26 2015-01-20 Nycomed Gmbh Isotopically substituted pantoprazole

Also Published As

Publication number Publication date
HK1160126A1 (en) 2012-08-10
JP2009502871A (ja) 2009-01-29
ZA200800303B (en) 2009-01-28
AU2006274036B2 (en) 2012-05-24
CN102134232A (zh) 2011-07-27
CN101268051A (zh) 2008-09-17
BRPI0614039A2 (pt) 2011-03-09
EP1910293A1 (en) 2008-04-16
EA016814B1 (ru) 2012-07-30
MX2008000901A (es) 2008-03-26
CN102134232B (zh) 2012-11-21
TW200714596A (en) 2007-04-16
AU2006274036A1 (en) 2007-02-01
WO2007012650A1 (en) 2007-02-01
CA2615670A1 (en) 2007-02-01
CN101268051B (zh) 2011-08-31
AR054584A1 (es) 2007-06-27
NO20080839L (no) 2008-02-18
CA2615670C (en) 2015-01-20
AU2006274036A2 (en) 2008-03-20
IL188773A (en) 2014-02-27
HK1125098A1 (en) 2009-07-31
IL188773A0 (en) 2008-08-07
KR20080037676A (ko) 2008-04-30
EA200800203A1 (ru) 2008-08-29
KR101358509B1 (ko) 2014-02-05
JP5448448B2 (ja) 2014-03-19
TWI394750B (zh) 2013-05-01

Similar Documents

Publication Publication Date Title
CA2615678C (en) Isotopically substituted pantoprazole
EP0654471B1 (en) Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and process for preparing the same
IE58363B1 (en) Pyridine derivatives and their production
JPH0572391B2 (es)
CA2615670C (en) Isotopically substituted proton pump inhibitors
SK109999A3 (en) Compounds for inhibition of gastric acid secretion
US5859030A (en) Substituted arylalkylthioalkylthiopyridines for use in the control of helicobacter bacteria
WO2000020391A1 (fr) Derives pyridine disubstitues en position 2,3, procede de preparation associe, compositions de medicament contenant ces derives, et intermediaires servant dans cette preparation
JPH05117268A (ja) ピリジン化合物
US7601737B2 (en) Isotopically substituted proton pump inhibitors
WO1997032854A1 (fr) Derives de 2-sulfinylnicotinamide, intermediaire de ces derives, procede pour produire ces derives et composition medicinale contenant ces derives comme ingredient actif
RU2154062C2 (ru) Замещенные арилтиоалкилтиопиридины, способ их получения, лекарственное средство на их основе и способ получения лекарственного средства.
US20070219236A1 (en) Dialkoxy-Imidazopyridines Derivatives
CA2447675A1 (en) Novel pyridylmethylaminopyrimidines
CZ2001993A3 (cs) 2,3-Disubstituovaný pyridinový derivát, způsob jeho přípravy, farmaceutický prostředek který jej obsahuje a jeho meziprodukt

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 JUL 2016 BY CPA GLOBAL

Effective date: 20130613

LAPS Patent lapsed